Jones Mitchell Lawrence 4

4 · PALISADE BIO, INC. · Filed Jul 8, 2026

AI-generated summary of this filing

Updated Jul 8, 2026

Palisade Bio CMO Jones Receives RSUs, Sells Shares

What Happened

Jones Mitchell Lawrence, Chief Medical Officer of Palisade Bio (PALI), had 131,167 restricted stock units (RSUs) settle into common shares on July 6, 2026. Following that settlement, he sold 51,880 shares in the open market on July 7, 2026 at a weighted average price of $2.05, generating proceeds of about $106,536. The sale was disclosed as a tax-withholding sale related to the RSU settlement.
Net result: 131,167 shares were issued on vesting and, after the sale of 51,880 shares to cover taxes, the reporting person retained a net increase of 79,287 shares from this vesting event. The open-market sale prices ranged from $2.045 to $2.06.

Key Details

Transaction dates: RSU settlement (conversion) on 2026-07-06; open-market sale on 2026-07-07.
Sale price: weighted average $2.05 (range $2.045–$2.06); proceeds ≈ $106,536.
Shares acquired via settlement: 131,167 RSUs converted to 131,167 shares (F1, F5).
Shares sold to cover taxes: 51,880 (F3). Net added shares from vesting after the sale: 79,287.
Other holdings noted: filing references 1,459 shares from the company ESPP acquired May 20, 2026 (F2).
Vesting schedule note: the RSUs vest 1/6 on July 6, 2026 and quarterly thereafter over 10 quarters, subject to continued service (F6).
Filing: Form 4 filed 2026-07-08 reporting the July 6–7 transactions; this appears to be within the typical two-business-day Form 4 filing window.
Derivative explanation: the RSU settlement is recorded as a conversion/exercise-type transaction (derivative code M) converting contingent RSUs into common shares.

Context

This was primarily a settlement of vested RSUs with a partial open-market sale to satisfy tax withholding—routine compensation-related activity rather than a pure investment purchase or directional trade. The sale does not necessarily indicate a change in the insider’s view of the company.

Form 4

Period: 2026-07-06

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-07-06+131,167→ 145,889 total
Sale
Common Stock
[F3][F4]
2026-07-07$2.05/sh−51,880$106,536→ 94,009 total
Exercise/Conversion
Restricted Stock Units
[F5][F6]
2026-07-06−131,167→ 655,833 total
→ Common Stock (131,167 underlying)

Footnotes (6)

[F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs") granted on February 9, 2026.
[F2]Includes 1,459 shares acquired under the Issuer's Employee Stock Purchase Plan on May 20, 2026.
[F3]The sale reported in this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.045 to $2.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
[F6]The RSUs shall vest with respect to 1/6th of the shares on July 6, 2026 and quarterly thereafter over the following 10 quarters, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Signature

/s/ Ryker Willie, Attorney-in-Fact for Mitchell Lawrence Jones|2026-07-08

1 file